254 related articles for article (PubMed ID: 19429444)
21. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes.
Han S; Li T; Ellis E; Strom S; Chiang JY
Mol Endocrinol; 2010 Jun; 24(6):1151-64. PubMed ID: 20371703
[TBL] [Abstract][Full Text] [Related]
22. Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor.
Harant H; Spinner D; Reddy GS; Lindley IJ
J Cell Biochem; 2000 Apr; 78(1):112-20. PubMed ID: 10797570
[TBL] [Abstract][Full Text] [Related]
23. A cardiotonic steroid bufalin-induced differentiation of THP-1 cells. Involvement of Na+, K(+)-ATPase inhibition in the early changes in proto-oncogene expression.
Numazawa S; Inoue N; Nakura H; Sugiyama T; Fujino E; Shinoki M; Yoshida T; Kuroiwa Y
Biochem Pharmacol; 1996 Jul; 52(2):321-9. PubMed ID: 8694857
[TBL] [Abstract][Full Text] [Related]
24. Mechanistic studies to evaluate the enhanced antiproliferation of human keratinocytes by 1alpha,25-dihydroxyvitamin D(3)-3-bromoacetate, a covalent modifier of vitamin D receptor, compared to 1alpha,25-dihydroxyvitamin D(3).
Chen ML; Ray S; Swamy N; Holick MF; Ray R
Arch Biochem Biophys; 1999 Oct; 370(1):34-44. PubMed ID: 10496974
[TBL] [Abstract][Full Text] [Related]
25. 1α-Dihydroxyvitamin D3 and Retinoic Acid Increase Nuclear Vitamin D Receptor Expression in Monocytic THP-1 Cells.
Uchida H; Hasegawa Y; Takahashi H; Makishima M
Anticancer Res; 2016 Dec; 36(12):6297-6301. PubMed ID: 27919949
[TBL] [Abstract][Full Text] [Related]
26. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor.
Dunlop TW; Väisänen S; Frank C; Molnár F; Sinkkonen L; Carlberg C
J Mol Biol; 2005 Jun; 349(2):248-60. PubMed ID: 15890193
[TBL] [Abstract][Full Text] [Related]
27. (23S)- and (23R)-25-dehydro-1alpha-hydroxyvitamin D(3)-26,23-lactone function as antagonists of vitamin D receptor-mediated genomic actions of 1alpha,25-dihydroxyvitamin D(3).
Ishizuka S; Miura D; Ozono K; Saito M; Eguchi H; Chokki M; Norman AW
Steroids; 2001; 66(3-5):227-37. PubMed ID: 11179730
[TBL] [Abstract][Full Text] [Related]
28. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
Kumagai T; Shih LY; Hughes SV; Desmond JC; O'Kelly J; Hewison M; Koeffler HP
Cancer Res; 2005 Mar; 65(6):2488-97. PubMed ID: 15781666
[TBL] [Abstract][Full Text] [Related]
29. Resistance to 1,25D-induced differentiation in human acute myeloid leukemia HL60-40AF cells is associated with reduced transcriptional activity and nuclear localization of the vitamin D receptor.
Garay E; Donnelly R; Wang X; Studzinski GP
J Cell Physiol; 2007 Dec; 213(3):816-25. PubMed ID: 17520689
[TBL] [Abstract][Full Text] [Related]
30. A novel inborn error in the ligand-binding domain of the vitamin D receptor causes hereditary vitamin D-resistant rickets.
Malloy PJ; Zhu W; Zhao XY; Pehling GB; Feldman D
Mol Genet Metab; 2001 Jun; 73(2):138-48. PubMed ID: 11386849
[TBL] [Abstract][Full Text] [Related]
31. 24-Oxo metabolites of vitamin D3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation.
Shiohara M; Uskokovic M; Hisatake J; Hisatake Y; Koike K; Komiyama A; Koeffler HP
Cancer Res; 2001 Apr; 61(8):3361-8. PubMed ID: 11309293
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of VDR-mediated transcription by phosphorylation: correlation with increased interaction between the VDR and DRIP205, a subunit of the VDR-interacting protein coactivator complex.
Barletta F; Freedman LP; Christakos S
Mol Endocrinol; 2002 Feb; 16(2):301-14. PubMed ID: 11818502
[TBL] [Abstract][Full Text] [Related]
33. Effects of MAPK signaling on 1,25-dihydroxyvitamin D-mediated CYP24 gene expression in the enterocyte-like cell line, Caco-2.
Cui M; Zhao Y; Hance KW; Shao A; Wood RJ; Fleet JC
J Cell Physiol; 2009 Apr; 219(1):132-42. PubMed ID: 19097033
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D receptor (VDR) localization in human promyelocytic leukemia cells.
Wu-Wong JR; Nakane M; Ma J; Dixon D; Gagne G
Leuk Lymphoma; 2006 Apr; 47(4):727-32. PubMed ID: 16690532
[TBL] [Abstract][Full Text] [Related]
35. 1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin.
Li XY; Boudjelal M; Xiao JH; Peng ZH; Asuru A; Kang S; Fisher GJ; Voorhees JJ
Mol Endocrinol; 1999 Oct; 13(10):1686-94. PubMed ID: 10517670
[TBL] [Abstract][Full Text] [Related]
36. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
Hedlund TE; Moffatt KA; Miller GJ
Endocrinology; 1996 May; 137(5):1554-61. PubMed ID: 8612485
[TBL] [Abstract][Full Text] [Related]
37. Natriuretic effect of bufalin in isolated rat kidneys involves activation of the Na+-K+-ATPase-Src kinase pathway.
Arnaud-Batista FJ; Costa GT; Oliveira IM; Costa PP; Santos CF; Fonteles MC; Uchôa DE; Silveira ER; Cardi BA; Carvalho KM; Amaral LS; Pôças ES; Quintas LE; Noël F; Nascimento NR
Am J Physiol Renal Physiol; 2012 Apr; 302(8):F959-66. PubMed ID: 22237798
[TBL] [Abstract][Full Text] [Related]
38. The impact of chromatin organization of vitamin D target genes.
Carlberg C; Dunlop TW
Anticancer Res; 2006; 26(4A):2637-45. PubMed ID: 16886674
[TBL] [Abstract][Full Text] [Related]
39. Hereditary vitamin D-resistant rickets (HVDRR) owing to a heterozygous mutation in the vitamin D receptor.
Malloy PJ; Zhou Y; Wang J; Hiort O; Feldman D
J Bone Miner Res; 2011 Nov; 26(11):2710-8. PubMed ID: 21812032
[TBL] [Abstract][Full Text] [Related]
40. ERK signaling mediates the induction of inflammatory cytokines by bufalin in human monocytic cells.
Kurosawa M; Numazawa S; Tani Y; Yoshida T
Am J Physiol Cell Physiol; 2000 Mar; 278(3):C500-8. PubMed ID: 10712238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
